Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Covid-19 pandemic: a deep dive into the UK’s ACCORD programme

To accelerate drugs through the early stages of clinical development and into large-scale UK studies, the UK Government’s Covid-19 Therapeutics Taskforce has created the ACCORD programme, with BerGenBio’s bemcentinib the first drug to be fast-tracked through the scheme. The company’s Mewburn Ellis patent attorney Rob Andrews explains the promise of this drug against the novel coronavirus and why taking part in the programme is beneficial for pharma companies.

Close
Close
Close

Go Top